{"entity":{"id":"nct06423326","kind":"trial","name":"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of cisplatin, gemcitabine and nab-paclitaxel in pancreatic cancer, run by Emory University, now recruiting.","summary":"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT06423326 by Emory University, with a registry enrolment figure of 36 participants, started 2024-08-06 and due to reach its primary completion in 2026-12-31. Interventions recorded: Biopsy; Biospecimen Collection; Cisplatin; Computed Tomography; Gemcitabine; Magnetic Resonance Imaging; Nab-paclitaxel; Pancreatic Surgical Procedure. Conditions listed: Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma; Stage I Pancreatic Cancer AJCC v8; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8. Primary outcome: Clinical Response Rate to Neoadjuvant Chemotherapy. Pancreatic eligibility wording from the registry: \"* Histologically or cytologically confirmed - resectable and borderline resectable pancreatic ductal adenocarcinoma\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06423326","url":"https://clinicaltrials.gov/study/NCT06423326"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["cisplatin","gemcitabine","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06423326","phase":"2","setting":"A Single-Arm Phase II Clinical Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma","sponsor":"Emory University","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06423326/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}